HLN vs. HIK, HCM, INDV, AMYT, BMK, AGY, APH, BXP, ANCR, and EAH
Should you be buying Haleon stock or one of its competitors? The main competitors of Haleon include Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Benchmark (BMK), Allergy Therapeutics (AGY), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), and ECO Animal Health Group (EAH). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Hikma Pharmaceuticals (LON:HIK) and Haleon (LON:HLN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership.
Haleon has higher revenue and earnings than Hikma Pharmaceuticals. Haleon is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Hikma Pharmaceuticals had 1 more articles in the media than Haleon. MarketBeat recorded 1 mentions for Hikma Pharmaceuticals and 0 mentions for Haleon. Haleon's average media sentiment score of 0.59 beat Hikma Pharmaceuticals' score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.
Hikma Pharmaceuticals received 788 more outperform votes than Haleon when rated by MarketBeat users. Likewise, 70.56% of users gave Hikma Pharmaceuticals an outperform vote while only 27.78% of users gave Haleon an outperform vote.
37.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.7% of Haleon shares are owned by institutional investors. 30.6% of Hikma Pharmaceuticals shares are owned by company insiders. Comparatively, 18.3% of Haleon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Haleon has a net margin of 9.64% compared to Haleon's net margin of 6.61%. Haleon's return on equity of 8.81% beat Hikma Pharmaceuticals' return on equity.
Hikma Pharmaceuticals pays an annual dividend of GBX 57 per share and has a dividend yield of 3.0%. Haleon pays an annual dividend of GBX 6 per share and has a dividend yield of 1.9%. Hikma Pharmaceuticals pays out 8,507.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Haleon pays out 5,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Hikma Pharmaceuticals currently has a consensus target price of GBX 2,050, suggesting a potential upside of 6.38%. Haleon has a consensus target price of GBX 356, suggesting a potential upside of 10.59%. Given Hikma Pharmaceuticals' higher possible upside, analysts clearly believe Haleon is more favorable than Hikma Pharmaceuticals.
Summary
Hikma Pharmaceuticals beats Haleon on 12 of the 18 factors compared between the two stocks.
Get Haleon News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
